Anti-NMDA receptor encephalitis and autoimmune diseases
Anti-NMDA receptor encephalitis is an acute autoimmune disease that has attracted attention in recent years because of the increasing cases of this disease. It presents a multistage illness progressing from initial psychiatric symptoms to memory disturbances, seizures, dyskinesia and catatonia. The treatments include first-line immunotherapies: steroids, intravenous immunoglobulin (IVIG) or plasmapheresis (or plasma exchange); and second-line immunotherapy such as rituximab or cyclophosphamide. This disease occurs more often in females than in males. A proportion of female patients have also been detected with ovarian tumors. The cause of this disease is often unknown. The pathogenic mechanism of a proportion of patients may be related to virus infection, tumor, and vaccination. Several anti-NMDA receptor encephalitis cases have been reported to be related to vaccination against H1N1 influenza or tetanus, diphtheria, pertussis, and poliomyelitis and Japanese encephalitis vaccination. In addition, herpes simplex encephalitis was reported to be associated with anti-NMDA receptor encephalitis. Similar to other autoimmune diseases, Anti-NMDA receptor encephalitis may not be diagnosed at an early stage that may lead to a delay in treatment and unsatisfactory outcomes. Researches on biological biomarkers to help early diagnose are as important as those on medicine development. In this special issue, we seeks reviews and original research papers focusing on a wide range of Anti-NMDA receptor encephalitis
and other autoimmune diseases studies.
Topics of interest include, but are not limited to:
· Genetic biomarker
· Drug development
· Pathogenic mechanism
Prof. Hsiuying Wang
Manuscripts should be submitted online at https://jour.ipublishment.com/bri by registering and logging into this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.
Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and written in clear, concise English and should contain all essential data in order to make the presentation clear and the results of the study replicable. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see